Venture Investors Health Fund

Day Two HLTH USA Top 3 topics are: AI, AI, AI.

Rivermark Medical, a leader in minimally invasive solutions for Benign Prostatic Hyperplasia (BPH), today announced the close of a $30 million Series C financing round, including new investors Venture Investors Health Fund, Time BioVentures, and an unnamed strategic investor. Funds will advance the clinical development of Rivermark's flagship product, the FloStent™ System, designed to restore urinary function for BPH patients. The device, currently in clinical development, offers a minimally invasive approach with quick recovery times, reversibility, and suitability for outpatient procedures. "We're grateful for the support of our investors as we progress toward bringing the FloStent System to market," said Adam Kadlec, President and CEO of Rivermark Medical. "This financing will accelerate our clinical programs and our path to commercialization, providing a new solution for the millions affected by BPH." https://lnkd.in/gZRSitdc

"We are excited to welcome Saira, Heather, and Bill to our Board," said Roland Green, CEO and Chairman of Invenra. "Their remarkable achievements in biotherapeutics development, commercialization, and strategic leadership align perfectly with Invenra's mission to advance novel bispecific antibody-based therapeutics. Their insights and guidance will be pivotal as we forge new strategic partnerships and expand our therapeutic portfolio." https://lnkd.in/gK9F7mEt

Invenra’s collaboration partner, Exelixis, Inc. (NASDAQ: EXEL) has announced the initiation of the dose-escalation stage of the first-in-human phase 1 clinical trial of XB010 in patients with locally advanced or metastatic solid tumors.

Congratulations to EnsoData on their acquisition of sleep testing diagnostic technology from Resonea aimed at reducing the cost of systematically addressing sleep apnea across large patient populations. https://lnkd.in/gWZdq9-T

"We are proud to have secured this substantial funding, which will advance our mission to radically change the way surgeons mark and locate their intended target for removal by turning their existing surgical instruments into intelligent tracking devices that elevate the standard of care in soft tissue oncologic procedures," says Jason Pesterfield, President and CEO of Elucent Medical. "With the support of our investors, we are poised to accelerate the commercialization of our EnVisio® and SmartClip® technologies, empowering healthcare providers with innovative tools to improve patient outcomes." https://lnkd.in/g--75hxc

Inspirational and educational day at the Autism Science Foundation “Day of Learning.” Great talks by all the speakers, including Dr Ami Klin, co-founder of Earlitec. #autismsciencefd,#Earlitec, #ventureinvestors

The great progress at ViaLase continues. This preeminent femtosecond laser team in ophthalmology has developed the first femto laser treatment for glaucoma. Proud to be part of progress and journey. #ventureinvestors

#PortfolioCompanySuccessStories